Blog
-
Research updates
28 August 2019
Unlocking the potential of immunotherapy for ovarian cancer patients
Immunotherapy is the focus of our 14th HHMT International Forum on Ovarian Cancer. Prof Iain McNeish and Dr Sarah Spear explain what it is and why it's such an exciting area of ovarian cancer research
-
Research updates
25 March 2019
OVPSYCH2: Research into survivorship support for ovarian cancer patients
Supported by Ovarian Cancer Action, OVPSYCH2 was the first randomised study to offer psychological support to ovarian cancer patients in the UK. Research into survivorship support for ovarian cancer patients is vital in improving quality of life for those affected by ovarian cancer.
-
"I loved my experience at the lab, and hearing about Jon's work was the highlight of the day"
Gift Hamisi has a family history of ovarian cancer, and was recently tested for the BRCA gene mutation, to discover if she also faced a high risk. We invited her to meet Dr Jonathan Krell at the Ovarian Cancer Research Centre, whose work focuses on hereditary mutations.
-
Research updates
08 March 2019
Prof. McNeish tackles PTEN-mutated ovarian cancers
Why are some ovarian cancers harder to treat, and how can we help our immune system fight them? Professor Iain McNeish explains
-
-
Research updates
26 March 2018
"If we are to make a major difference in our fight against ovarian cancer we must develop a screening tool"
Your support means that Professor Ahmed Ahmed and his team at the University of Oxford have been able to make ground breaking discoveries in the early detection of ovarian cancer. This work could be the key to saving thousands of women’s lives every year. You can help fund research into the development of the world’s first screening tool for ovarian cancer by donating £10 today.
-
Research updates
28 July 2017
Why do we fund medical research?
We know that ovarian cancer is deadly. That it takes the lives of too many women. And we’re on a mission to stop these women dying before their time. At the heart of this mission is the real action we’re taking. Libby van den Bosch examines how the research we fund is making a real difference to the lives of women.
-
Should we still be talking about ‘ovarian’ cancer?
Last week an article entitled "Why are we still talking about 'ovarian' cancer" was published and has since been widely shared on the internet. Our Cancer Prevention Officer, Jo, takes a look at the implications.
-
Could osteoporosis drugs be used to prevent cancer in BRCA1 gene carriers?
Our Health Projects Manager Ross responds to reports of a new 'holy grail' in cancer prevention, which suggests drugs more commonly used to treat osteoporosis could be used to prevent ovarian and breast cancer in women who carry a BRCA1 gene mutation.
